NASH Monotherapy: A tour of the FXR Agonist Menagerie

Time: 5:00 pm

Details:

• Reviewing the development of FXR agonists – from BAs to targeted small molecules
• Discussing PD and efficacy measures of FXR in NASH
• Understanding safety and tolerability of FXR agonists for NASH

Speakers: